Merck (NYSE:MRK) is doubling down on China's biotech boomthis time with a $2 billion licensing deal for a potential blockbuster heart drug from Jiangsu Hengrui Pharmaceuticals. The deal gives ...

the latest in a series of deals U.S. drugmakers have recently signed with China-based firms. Large drugmakers including Merck and Eli Lilly (LLY.N), opens new tab have turned to Chinese biotechs ...

Recently, Hong Chow, Executive Vice President of Merck and Head of China & International for Merck Healthcare, led a delegation on the first "China Visit" of 2025, reaffirming that collaboration ...

This year's two sessions is a reconfirmation of the confidence that Merck has in China because the Chinese government has set the economic growth target at 5 percent, focusing more on innovation ...

Merck (NYSE:MRK) is doubling down on China's biotech boomthis time with a $2 billion licensing deal for a potential blockbuster heart drug from Jiangsu Hengrui Pharmaceuticals. The deal gives Merck ...

bought global rights to China-based United Laboratories International’s weight-loss drug candidate in a deal worth up to $2 billion. Merck last year signed a licensing deal worth up to $2 ...

Most recently, Danish drugmaker Novo Nordisk bought global rights to China-based United Laboratories International's weight-loss drug candidate in a deal worth up to $2 billion. Merck last year ...

Per the deal terms, Merck (NYSE:MRK) will receive exclusive rights to develop, manufacture, and commercialize HRS-5346 globally except in Greater China. In exchange, the Rahway, New Jersey-based ...

China’s factory activity expanded at the fastest pace in a year in March, welcome news for the world’s No. 2 economy before expected US tariffs that could further strain trade ties. The ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

The moves in China by the likes of Merck also come as the industry stares down a wave of generic drugs this year that has made the issue of securing new candidates all the more pressing.